Aquestive Therapeutics, Inc. AQST Debt Issuance Cost Amortization
Debt Issuance Cost Amortization at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s debt issuance cost amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s debt issuance cost amortization?
- Aquestive Therapeutics, Inc. (AQST) reported debt issuance cost amortization of $2.29M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s debt issuance cost amortization changed year-over-year?
- Aquestive Therapeutics, Inc.'s debt issuance cost amortization decreased by 16.9% year-over-year, from $2.75M to $2.29M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s debt issuance cost amortization?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s debt issuance cost amortization has grown at a 31.0% compound annual growth rate (CAGR), from $3.73M to $11M.
- What does debt issuance cost amortization mean?
- Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).